New anti-tuberculosis drugs in clinical trials with novel mechanisms of action.
Tuberculosis is a major health problem worldwide, with approximately 1.7 million people dying annually from the disease. The long current drug regimen, the emergence of drug resistant strains and HIV co-infection have resulted in a resurgence in research efforts to address the urgent need for new anti-tuberculosis drugs. A number of new potential anti-tuberculosis drug candidates with novel modes of action have entered clinical trials in recent years. These agents are most likely to be effective against resistant strains. We provide a concise review of their structure-activity relationships, in vitro and in vivo activity, pharmacokinetics, mechanism of action and combination regimens.
The Open University, Walton Hall, Milton Keynes MK7 6AA, United Kingdom.
Emma C
EC
Rivers
Ricardo L
RL
Mancera
D000818:Animals; D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications; D006801:Humans; D013329:Structure-Activity Relationship; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology
D000995:Antitubercular Agents